RGNT — REGENTIS BIOMATERIALS LTD.
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1912966 ·
Israel
Last close
$2.16
Market Cap
$11.19M
52W High
$3.96
52W Low
$1.82
ADV30
19,139
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 7,618,000 | 7,378,000 | 2,874,000 |
| Jun 2025 | — | — | — | — | 475,000 | 189,000 | 44,807,000 |
| Dec 2024 | — | — | — | — | 482,000 | 229,000 | 41,586,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-55,794,000
Inventory
—
Receivables
$230,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,619,000 | -13,648,000 | 7,618,000 | 2,874,000 | — | -1,375,000 |
| Dec 2024 | 0 | 932,000 | 4,801,000 | 482,000 | 41,586,000 | — | -641,000 |
| Dec 2023 | 0 | -1,931,000 | -4,132,000 | 360,000 | 46,265,000 | — | -1,220,000 |
| Dec 2022 | 0 | -1,407,000 | -1,449,000 | 1,717,000 | 43,778,000 | — | -1,504,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALUR | ALLURION TECHNOLOGIES, INC. | $11.25M | $0.75 | — |
| SINT | Sintx Technologies, Inc. | $10.50M | $2.43 | — |
| NXL | Nexalin Technology, Inc. | $10.34M | $0.48 | — |
| NIMU | NON INVASIVE MONITORING SYSTEMS INC /FL/ | $12.38M | $0.08 | — |
| ALRTF | ALR Technologies SG Ltd. | $9.68M | $0.01 | — |
News headlines (Yahoo Finance, 1h cache)
Regentis Biomaterials (RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair
2026-05-26 19:40 · Yahoo
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
2026-04-16 12:30 · Yahoo
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
2026-03-17 12:30 · Yahoo
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
2026-02-24 21:15 · Yahoo
Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch
2026-02-24 18:11 · Yahoo
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
2026-02-19 13:30 · Yahoo
Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs
2026-02-17 13:30 · Yahoo
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
2026-02-04 13:33 · Yahoo
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
2026-01-29 13:33 · Yahoo
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
2026-01-20 13:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.